Meeting
2017 Gastrointestinal Cancers Symposium
Cetuximab and bevacizumab in addition to chemotherapy first-line for left-side metastatic colorectal cancer: A cost-effectiveness analysis.
Authors
Yanqiao Zhang
The Harbin Medical University Cancer Hospital, Harbin, People's Republic of China, Harbin, China
Yanqiao Zhang , Tongsen Zheng , Maobai Liu , Te Li , Bin Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 732)
DOI
10.1200/JCO.2017.35.4_suppl.732
Abstract #
732
Poster Bd #
K20
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.
First Author: Gong Chen
Poster
2021 Gastrointestinal Cancers Symposium
Cost-effectiveness of cetuximab + FOLFIRI versus bevacizumab + FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
First Author: Ilse Van Oostrum
Poster
2024 ASCO Annual Meeting
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.
First Author: Wenhua Li
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz